The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or hematocrit (HCT) with suspicion of pneumonia. Results are expected later in 2022.